They had just one drug at the time, Vancomycin I believe. The form that they had though was to be use to treat Cdifficile bactieria causing severe interestinal problems in hospitals. At the time, there was also threat of a generic form coming out within months. I owned the stock at the time at $6, watched it go to $12.50, then back to $7 on concerns over the generic. A few months later, the stock went to $20 ! However I was out of the stock at $7.50 the very week it made it's lows, and with attack after attack about how the generic would kill sales.
They did post $.14 non gaap for the Dec qtr, but there were near zero taxes. Analysts say $.55+ for 2015, but is that non gaap, taxed(at what %) ?
Auryxia supposedly did 57 scripts for the week ended 2/6. I'd like a link on that. thanks
If historically this is the case, I don't get why the stock has been hammered before seeing how things go for much longer than this. I mean from what I understand, there are only 2 or 3 insureance companys covering right now out of a dozen of more. Main question I have is, how long for the majority of Insuranace companies to cover Auryxia ?
you wouldn't know it by the way this stock is acting
You've seen KERX go from $18 right before approval to $11 after approval. It's like the stock was dead on approval. I've heard zero fundamental reasons for this. The warning lable is bogus, so forget that one. NCE would be fine, but isn't needed with KERX having patents on oral use out to 2024. KERX is in phase lll for use of Auryxia for non dialysis CKD patients with anemia. That market would be 3-4 times as big as the current one. Bottom line is, shorts may have initially used the warnng label and lack of NCE status at first to keep the stock down, but now they're playing with fire IMO.
We know KERX has the ONLY phosphate binder that both controls phosphate levels & raises lV iron levels. Obviously the possibility for CKD patients with anemia to have one drug that they can take that will control their phosphate levels & may allow them to not have to take their iron lV regiments is exciting. If I were a nephrologist or ran a kindey dialysis center, KERX's Auryxia would be a welcome new drug to try.
What we don't know is, why when the institutions are raising their share counts, and analysts raising their target prices, would the stock be tanking almost every day. Do the shorts really think this is a bad drug, or are they just trying to manipulate the stock ? Here is an article I found interesting from 2007
pocilijko- From what I understand, AXAS has 20% hedges on $85 oil for 2015- is that right.? What does oil have to be at for them to breakeven, and how much in EPS in 2015 might they make at lets say $60 oil ? Lastly, how would you value the stock at this point ? I understand we can't go by any PE assumptions till oil stabalizes, but what's your short term target on the stock ?
gary, I'm with you. Initial sales numbers shown yesterday show a slow start, but if you look at so many blockbuster drugs, they've started off very slow as well.